To: Dr. John M. de Castro who wrote (2539 ) 3/18/2000 4:41:00 PM From: Walter Morton Read Replies (1) | Respond to
I am appalled by the CIST management decision to NOT inform its shareholders in a timely fashion about new inventions and research collaborations:written in 1998 and not available to shareholder until 2000 , the following statement is made:has claims protecting the use of a mutant form of IL-1b as an intranasal vaccine adjuvant, and , fourth, is based on an invention disclosed to DUKE in an Invention Disclosure Form which was assigned File # 1689 and which is incorporated in its entirety as Exhibit A of this AGREEMENT. two years later , through my research, that this intranasal vaccine adjuvant is linked to a multi-million dollar HIV vaccine project at Duke University (see my last few posts to the CIST discussion board).emedtrade.com ) to help CIST find a buyer, there was no mention of this agreement in the research collaboration section of the web page. Furthermore, there was no mention of the DUKE UNIVERSITY royalty payments nor the significant milestone payments to be paid to DUKE UNIVERSITY ( Message 12905667 ).CIST shareholders have good cause to bring suit against CIST management for lack of timely disclosure of significant events.
